JP2022534788A5 - - Google Patents
Info
- Publication number
- JP2022534788A5 JP2022534788A5 JP2021571896A JP2021571896A JP2022534788A5 JP 2022534788 A5 JP2022534788 A5 JP 2022534788A5 JP 2021571896 A JP2021571896 A JP 2021571896A JP 2021571896 A JP2021571896 A JP 2021571896A JP 2022534788 A5 JP2022534788 A5 JP 2022534788A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- approximately
- compound
- diffraction pattern
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025101917A JP2025138706A (ja) | 2019-06-07 | 2025-06-18 | Ｓｈｐ２阻害物質である｛６－［（２－アミノ－３－クロロピリジン－４－イル）スルファニル］－３－［（３ｓ，４ｓ）－４－アミノ－３－メチル－２－オキサ－８－アザスピロ［４．５］デカン－８－イル］－５－メチルピラジン－２－イル｝メタノールの固体形態 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962858837P | 2019-06-07 | 2019-06-07 | |
| US62/858,837 | 2019-06-07 | ||
| PCT/US2020/036137 WO2020247643A1 (en) | 2019-06-07 | 2020-06-04 | Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025101917A Division JP2025138706A (ja) | 2019-06-07 | 2025-06-18 | Ｓｈｐ２阻害物質である｛６－［（２－アミノ－３－クロロピリジン－４－イル）スルファニル］－３－［（３ｓ，４ｓ）－４－アミノ－３－メチル－２－オキサ－８－アザスピロ［４．５］デカン－８－イル］－５－メチルピラジン－２－イル｝メタノールの固体形態 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022534788A JP2022534788A (ja) | 2022-08-03 |
| JP2022534788A5 true JP2022534788A5 (https=) | 2023-06-07 |
Family
ID=71787182
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571896A Pending JP2022534788A (ja) | 2019-06-07 | 2020-06-04 | Ｓｈｐ２阻害物質である｛６－［（２－アミノ－３－クロロピリジン－４－イル）スルファニル］－３－［（３ｓ，４ｓ）－４－アミノ－３－メチル－２－オキサ－８－アザスピロ［４．５］デカン－８－イル］－５－メチルピラジン－２－イル｝メタノールの固体形態 |
| JP2025101917A Pending JP2025138706A (ja) | 2019-06-07 | 2025-06-18 | Ｓｈｐ２阻害物質である｛６－［（２－アミノ－３－クロロピリジン－４－イル）スルファニル］－３－［（３ｓ，４ｓ）－４－アミノ－３－メチル－２－オキサ－８－アザスピロ［４．５］デカン－８－イル］－５－メチルピラジン－２－イル｝メタノールの固体形態 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025101917A Pending JP2025138706A (ja) | 2019-06-07 | 2025-06-18 | Ｓｈｐ２阻害物質である｛６－［（２－アミノ－３－クロロピリジン－４－イル）スルファニル］－３－［（３ｓ，４ｓ）－４－アミノ－３－メチル－２－オキサ－８－アザスピロ［４．５］デカン－８－イル］－５－メチルピラジン－２－イル｝メタノールの固体形態 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11220501B2 (https=) |
| EP (1) | EP3980128A1 (https=) |
| JP (2) | JP2022534788A (https=) |
| KR (1) | KR20220019017A (https=) |
| CN (2) | CN115141205A (https=) |
| AU (1) | AU2020288631A1 (https=) |
| BR (1) | BR112021022635A2 (https=) |
| CA (1) | CA3142430A1 (https=) |
| IL (1) | IL288568A (https=) |
| MA (1) | MA56113A (https=) |
| MX (1) | MX2021014855A (https=) |
| PH (1) | PH12021552902A1 (https=) |
| SG (1) | SG11202112461QA (https=) |
| TW (1) | TW202112785A (https=) |
| WO (1) | WO2020247643A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3074690A1 (en) | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
| CN115141205A (zh) | 2019-06-07 | 2022-10-04 | 锐新医药公司 | Shp2抑制剂的固体形式 |
| WO2022259157A1 (en) | 2021-06-09 | 2022-12-15 | Novartis Ag | A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor |
| TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途 |
| KR20240055778A (ko) | 2021-09-01 | 2024-04-29 | 노파르티스 아게 | Tead 억제제를 포함하는 제약 조합물 및 암의 치료를 위한 이의 용도 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| TW200716594A (en) * | 2005-04-18 | 2007-05-01 | Neurogen Corp | Substituted heteroaryl CB1 antagonists |
| NZ713361A (en) * | 2009-08-17 | 2017-06-30 | Memorial Sloan Kettering Cancer Center | Heat shock protein binding compounds, compositions, and methods for making and using same |
| ES2699351T3 (es) * | 2014-01-17 | 2019-02-08 | Novartis Ag | Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2 |
| JO3517B1 (ar) * | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| EP4302834A3 (en) * | 2016-07-12 | 2024-07-17 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
| CA3074690A1 (en) | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
| MX2020010719A (es) | 2018-04-10 | 2020-11-06 | Revolution Medicines Inc | Composiciones de inhibidores de shp2, metodos para tratar el cancer y metodos para identificar a un sujeto con mutaciones en shp2. |
| CN115141205A (zh) | 2019-06-07 | 2022-10-04 | 锐新医药公司 | Shp2抑制剂的固体形式 |
-
2020
- 2020-06-04 CN CN202210564150.XA patent/CN115141205A/zh active Pending
- 2020-06-04 MX MX2021014855A patent/MX2021014855A/es unknown
- 2020-06-04 BR BR112021022635A patent/BR112021022635A2/pt not_active IP Right Cessation
- 2020-06-04 MA MA056113A patent/MA56113A/fr unknown
- 2020-06-04 EP EP20746488.4A patent/EP3980128A1/en active Pending
- 2020-06-04 TW TW109118750A patent/TW202112785A/zh unknown
- 2020-06-04 CA CA3142430A patent/CA3142430A1/en active Pending
- 2020-06-04 CN CN202080054905.0A patent/CN114190090A/zh active Pending
- 2020-06-04 AU AU2020288631A patent/AU2020288631A1/en not_active Abandoned
- 2020-06-04 SG SG11202112461QA patent/SG11202112461QA/en unknown
- 2020-06-04 JP JP2021571896A patent/JP2022534788A/ja active Pending
- 2020-06-04 PH PH1/2021/552902A patent/PH12021552902A1/en unknown
- 2020-06-04 WO PCT/US2020/036137 patent/WO2020247643A1/en not_active Ceased
- 2020-06-04 KR KR1020227000184A patent/KR20220019017A/ko not_active Ceased
-
2021
- 2021-02-26 US US17/187,504 patent/US11220501B2/en active Active
- 2021-11-29 US US17/537,113 patent/US12528807B2/en active Active
- 2021-12-01 IL IL288568A patent/IL288568A/en unknown
-
2025
- 2025-06-18 JP JP2025101917A patent/JP2025138706A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022534788A5 (https=) | ||
| JP7447071B2 (ja) | 固体形態 | |
| CN116685326A (zh) | Cdk抑制剂的共晶体 | |
| JP2022526438A5 (https=) | ||
| JP2007521340A5 (https=) | ||
| HUT71593A (en) | Diketopiperazines, pharmaceutical compositions containing and process for producing the compounds | |
| JP2023519891A5 (https=) | ||
| JP4142621B2 (ja) | 純結晶形態の５−クロロ−３−（４−メタンスルホニルフェニル）−６’−メチル−［２，３’］ビピリジニルおよび合成方法 | |
| JP2006528973A5 (https=) | ||
| TW202200594A (zh) | 一種glp-1受體激動劑的晶型a及其製備方法 | |
| JP2008513358A5 (https=) | ||
| JP6937322B2 (ja) | 置換ピペリジン化合物の塩 | |
| CN109937200B (zh) | 一种苯并呋喃类衍生物游离碱的晶型及制备方法 | |
| CN101243066A (zh) | 甲磺酸伊马替尼的δ和ε晶形 | |
| JP2012508719A (ja) | スニチニブマレートの新たな結晶形 | |
| JP2020521732A5 (https=) | ||
| JP2023541434A5 (https=) | ||
| JP2022523368A5 (https=) | ||
| CN102264726A (zh) | 新的舒尼替尼盐 | |
| JP2021535111A5 (https=) | ||
| JP2023521411A5 (https=) | ||
| JP2022535850A5 (https=) | ||
| JP2024518429A5 (https=) | ||
| JP2024525145A5 (https=) | ||
| JP2022540922A5 (https=) |